NCT02647125 is a Phase 2 clinical trial of Huachansu in Esophageal Squamous Cell Carcinoma, sponsored by Fudan University.

Who is sponsoring NCT02647125?

NCT02647125 is sponsored by Fudan University.

What drugs are being tested in NCT02647125?

Interventions in NCT02647125: Huachansu, thoracic radiation.

What condition does NCT02647125 study?

NCT02647125 studies Esophageal Squamous Cell Carcinoma.

Is NCT02647125 still recruiting?

NCT02647125 is currently completed. Last updated 23 November 2024.

Last reviewed 2024-11-23 · How we verify

NCT02647125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma

Completed Phase 2 Last updated 23 November 2024

What this trial tests

Phase 2 trial testing Huachansu in Esophageal Squamous Cell Carcinoma in 126 participants. Completed in 1 December 2022.

Timeline

1 September 2015

Primary endpoint
1 September 2022

1 December 2022

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	126
Start date	1 September 2015
Primary completion	1 September 2022
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

Huachansu — full drug profile →
thoracic radiation

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Local control rate
Time frame: the date of randomization until progression inside the irradiation field, up to 3 years.
The outcome measure will be assessed by every 3-month follow-up examinations.

Sponsor's own description

This primary objective of the trial is to study whether the local control of Huachansu plus thoracic radiotherapy is better compared to thoracic radiotherapy alone for patients with esophageal squamous cell carcinoma. It's a phase II study, 134 patients are expected to be recruited into the trial.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery.
Bordon KCF, Cologna CT, Fornari-Baldo EC, Pinheiro-Júnior EL, et al · · 2020 · cited 193× · PMID 32848750 · DOI 10.3389/fphar.2020.01132
Cardiac glycosides: Looking beyond heart failure and atrial fibrillation.
Omole JG, Udom GJ, Aturamu A, Agbana RD, et al · · 2025 · cited 4× · PMID 40324829 · DOI 10.4103/ijp.ijp_934_24
Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.
Liu Q, Shen J, Chen Y, Zhou J, et al · · 2025 · PMID 41021440 · DOI 10.1093/oncolo/oyaf325

Verify or expand the search:

Other trials of Huachansu

Trials testing the same drug.

NCT05594927 — Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With · Phase 3 · recruiting

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02647125 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 23 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02647125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing